KATHRYN SHUNNARAH: Open Payments
NPI 1699837104 · ROCKLEDGE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,814 in 235 payments from 50 companies in 2025. Trend: 2023 $3,518 · 2024 $5,914 · 2025 $5,814
Food & beverage: $4,545Long term medical supply or device loan: $1,000Education: $283
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 23 | $1,223 |
| Janssen Biotech, Inc. | 27 | $564 |
| AstraZeneca Pharmaceuticals LP | 18 | $470 |
| PFIZER INC. | 22 | $368 |
| Incyte Corporation | 12 | $294 |
| Merck Sharp & Dohme LLC | 11 | $246 |
| ABBVIE INC. | 8 | $178 |
| Astellas Pharma US Inc | 10 | $159 |
| Dendreon Pharmaceuticals LLC | 4 | $149 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $149 |
Products named: KISQALI, ENHERTU, TECVAYLI, RYBREVANT, ELREXFIO, KEYTRUDA, Xtandi, PROVENGE.
Industry payments across FL — which companies pay providers there.
